HPV Vaccines Not a Cause of Two Syndromes, Says EMA

Article

A review by the European Medicines Agency shows that the HPV vaccine does not cause complex regional pain syndrome and postural orthostatic tachycardia syndrome.

According to an eagerly awaited scientific review conducted by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee, the human papillomavirus (HPV) vaccination does not cause complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS).

The agency concluded that the vaccine, given to teenage girls and boys to protect them from cervical, anal, and/or other HPV-related cancers, as well as genital warts, shows no direct link between the three marketed vaccines-Cervarix, Gardasil/Silgard, and Gardasil-9-and the onset of either CRPS or POTS.

CRPS is a chronic pain syndrome, and POTS is a syndrome in which the heart rate increases to an abnormal level upon sitting or standing up. They both cause dizziness, fainting, headache, nausea, and fatigue, among other symptoms, and affect quality of life.

The committee reviewed published research, clinical trial data, and reports of potential side effects from patients and clinicians. Based on their conclusions from this review, the EMA does not recommend any modification in the way these vaccinations are given.

“The reports of CRPS and POTS after HPV vaccination are consistent with what would be expected in this age group,” they concluded.

The review was initially requested by Denmark in July. The Parliamentary Health Committee of Denmark is conducting their own independent review, having allocated 7 million kroner for the study.

In the United States, HPV vaccination is recommended for girls and boys age 11 to 12 years and through the age of 26 by the American Academy of Pediatrics as of 2012. Women up to the age of 26 and men up to the age of 21 should also be vaccinated if they have not received the full three-dose vaccine. According to the EMA, it is estimated that more than 63 million girls and women worldwide have been vaccinated with Gardasil/Silgard and more than 19 million with Cervarix.

In Europe, Gardasil has been approved since 2006 to protect against HPV-related cancers and genital warts caused by four HPV types (6, 11, 16, and 18) in both boys and girls. Gardasil-9 was approved in June of this year and protects against these four types plus five additional cancer-causing types-31, 33, 45, 52, and 58. Cervarix, available since 2007 in Europe, is approved in women and girls against HPV types 16 and 18. After their approval, the vaccines became part of national immunization programs in many European countries, including Denmark.

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content